Pieris Pharmaceuticals Inc. (PIRS) Given Outperform Rating at Oppenheimer Holdings Inc.
Oppenheimer Holdings Inc. reiterated their outperform rating on shares of Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) in a report released on Wednesday morning. Oppenheimer Holdings Inc. currently has a $10.00 target price on the stock.
Separately, Roth Capital reiterated a buy rating and set a $6.00 target price on shares of Pieris Pharmaceuticals in a research note on Wednesday, September 28th.
Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) opened at 1.9599 on Wednesday. The company has a 50 day moving average of $1.64 and a 200 day moving average of $1.79. Pieris Pharmaceuticals has a 52 week low of $1.26 and a 52 week high of $3.08. The firm’s market cap is $84.39 million.
Pieris Pharmaceuticals (NASDAQ:PIRS) last released its earnings results on Wednesday, August 10th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.01. Pieris Pharmaceuticals had a negative net margin of 346.01% and a negative return on equity of 52.21%. The firm earned $1.07 million during the quarter. On average, equities research analysts anticipate that Pieris Pharmaceuticals will post ($0.55) EPS for the current fiscal year.
Institutional investors have recently added to or reduced their stakes in the company. Lombard Odier Asset Management USA Corp raised its position in Pieris Pharmaceuticals by 20.3% in the second quarter. Lombard Odier Asset Management USA Corp now owns 3,166,915 shares of the company’s stock valued at $5,099,000 after buying an additional 533,965 shares in the last quarter. BVF Inc. IL purchased a new position in Pieris Pharmaceuticals during the second quarter valued at approximately $389,000. Sabby Management LLC raised its position in Pieris Pharmaceuticals by 823.4% in the second quarter. Sabby Management LLC now owns 1,615,992 shares of the company’s stock valued at $2,602,000 after buying an additional 1,440,992 shares in the last quarter. Frontier Wealth Management LLC purchased a new position in Pieris Pharmaceuticals during the second quarter valued at approximately $137,000. Finally, BlackRock Fund Advisors purchased a new position in Pieris Pharmaceuticals during the second quarter valued at approximately $113,000. Institutional investors and hedge funds own 45.79% of the company’s stock.
Pieris Pharmaceuticals Company Profile
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
Receive News & Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.